Zentalis Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
If you work at Zentalis Pharmaceuticals Inc and you would like to licence your ESG rating, please contact us. This ESG score for Zentalis Pharmaceuticals Inc indicates the company's reporting of the UN Sustainable Development Goals. Jump to the end of this webpage for potential risks for Zentalis Pharmaceuticals Inc based on industry, geography and marketcap.
Zentalis Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 4.0, social score of 4.6 and governance score of 4.0.
4.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 951 | Purple Biotech Ltd | 4.3 | High |
| 951 | Vectura Group Services Ltd | 4.3 | High |
| 969 | Zentalis Pharmaceuticals Inc | 4.2 | High |
| 969 | Botanix Pharmaceuticals Ltd | 4.2 | High |
| 969 | Arvinas Inc | 4.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Zentalis Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Zentalis Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Zentalis Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Zentalis Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Zentalis Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Zentalis Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Zentalis Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.